| Literature DB >> 33052319 |
Eric D Vidoni1, Amanda Szabo-Reed1, Chaeryon Kang2, Ashley R Shaw1, Jaime Perales-Puchalt1, George Grove2, Morgan Hamill3, Donovan Henry3, Jeffrey M Burns1, Charles Hillman3, Arthur F Kramer3,4, Edward McAuley5,4, Kirk I Erickson2.
Abstract
Full and diverse participant enrollment is critical to the success and generalizability of all large-scale Phase III trials. Recruitment of sufficient participants is among the most significant challenges for many studies. The novel SARS-CoV-2 coronavirus pandemic has further changed and challenged the landscape for clinical trial execution, including screening and randomization. The Investigating Gains in Neurocognition in an Intervention Trial of Exercise (IGNITE) study has been designed as the most comprehensive test of aerobic exercise effects on cognition and brain health. Here we assess recruitment into IGNITE prior to the increased infection rates in the United States, and examine new challenges and opportunities for recruitment with a goal of informing the remaining required recruitment as infection containment procedures are lifted. The results may assist the design and implementation of recruitment for future exercise studies, and outline opportunities for study design that are flexible in the face of emerging threats.Entities:
Keywords: COVID-19; Cognition; Disparity; Enrollment; Exercise; Screen-fail
Year: 2020 PMID: 33052319 PMCID: PMC7544598 DOI: 10.1016/j.conctc.2020.100666
Source DB: PubMed Journal: Contemp Clin Trials Commun ISSN: 2451-8654
Inclusion and exclusion criteria.
| Inclusion criteria | Exclusion criteria |
|---|---|
Age 65–80 yrs. Ambulatory without pain or the use of assisted walking devices Able to speak and read English Medical clearance by primary care physician (PCP) Living in community for duration of the study Reliable means of transportation No diagnosis of a neurological disease Telephone Interview of Cognitive Status score > 25 Cognitive adjudication decision of cognitively normal | Current diagnosis of an Axis I or II disorder including Major Depression History of major psychiatric illness including schizophrenia (not including general anxiety disorder or depression (Geriatric Depression Scale [GDS] ≥9) Current treatment for cancer – except non-melanoma skin cancer Neurological condition (MS, Parkinson's, Dementia) or brain injury (Stroke) Type I Diabetes, Insulin-dependent Type II Diabetes, uncontrolled Type II diabetes (defined as an HbA1c level > 10) Current alcohol or substance abuse or treatment for abuse in the past 5 years Current treatment for congestive heart failure, angina, uncontrolled arrhythmia, deep vein thrombosis (DVT) or another cardiovascular event Myocardial infarction, coronary artery bypass grafting, angioplasty or other cardiac condition in the past year Claustrophobia or inability to complete the MRI scan due to metal implants (pacemaker, stents) that are MR ineligible Color Blindness Engaging in >20 min of moderate intensity physical activity per day for 3 days or more per week Not local or able to travel 3 times per week to the exercise facility Traveling consecutively for 3 weeks or more during the study Unwillingness to be randomized to one of the three groups Current participation in an ongoing trial likely to influence exercise ability or cognitive function (e.g., mindfulness training). |
Fig. 1Screening and enrollment flow.
Study referral sources by demographics.
| Community Presentation | Active Ignite Participant | Prior Research Participant | Professional Word of Mouth | Non-Professional Word of Mouth | Print Advert | Direct | Social Media | TV/News | Website | Other | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Male | 10 (1.9%) | 19 (3.7%) | 34 (6.6%) | 11 (2.1%) | 19 (3.7%) | 17 (3.3%) | 254 (49.5%) | 6 (1.2%) | 13 (2.5%) | 53 (10.3%) | 77 (15%) | 513 |
| Female | 29 (3%) | 51 (5.3%) | 64 (6.7%) | 18 (1.9%) | 38 (4%) | 39 (4.1%) | 469 (49%) | 24 (2.5%) | 35 (3.7%) | 85 (8.9%) | 106 (11.1%) | 958 |
| Age 75+ | 11 (4.4%) | 5 (2%) | 16 (6.3%) | 5 (2%) | 8 (3.2%) | 6 (2.4%) | 146 (57.9%) | 2 (0.8%) | 10 (4%) | 16 (6.3%) | 27 (10.7%) | 252 |
| Age <75 | 28 (2.3%) | 65 (5.3%) | 82 (6.7%) | 24 (1.9%) | 49 (4%) | 52 (4.2%) | 582 (47.3%) | 28 (2.3%) | 41 (3.3%) | 122 (9.9%) | 158 (12.8%) | 1231 |
| African American | 2 (0.9%) | 5 (2.3%) | 3 (1.4%) | 3 (1.4%) | 4 (1.9%) | 5 (2.3%) | 141 (66.2%) | 0 (0%) | 8 (3.8%) | 17 (8%) | 25 (11.7%) | 213 |
| Asian | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 2 (11.1%) | 1 (5.6%) | 11 (61.1%) | 0 (0%) | 3 (16.7%) | 1 (5.6%) | 0 (0%) | 18 |
| White | 37 (3.2%) | 64 (5.5%) | 91 (7.8%) | 26 (2.2%) | 42 (3.6%) | 48 (4.1%) | 525 (45%) | 30 (2.6%) | 32 (2.7%) | 119 (10.2%) | 153 (13.1%) | 1167 |
| American Indian/Alaska Native | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (33.3%) | 0 (0%) | 2 (66.7%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 3 |
| Native Hawaiian/Pacific Islander | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (50%) | 1 (50%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 2 |
| Refused | 0 (0%) | 1 (3.2%) | 2 (6.5%) | 0 (0%) | 2 (6.5%) | 0 (0%) | 23 (74.2%) | 0 (0%) | 1 (3.2%) | 0 (0%) | 2 (6.5%) | 31 |
| Biracial | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 3 (100%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 3 |
| Other | 0 (0%) | 0 (0%) | 2 (13.3%) | 0 (0%) | 5 (33.3%) | 0 (0%) | 7 (46.7%) | 0 (0%) | 0 (0%) | 1 (6.7%) | 0 (0%) | 15 |
| Hispanic/Latino | 2 (4.1%) | 1 (2%) | 3 (6.1%) | 1 (2%) | 3 (6.1%) | 1 (2%) | 31 (63.3%) | 0 (0%) | 0 (0%) | 2 (4.1%) | 5 (10.2%) | 49 |
| Not Hispanic/Latino | 37 (2.6%) | 69 (4.9%) | 95 (6.8%) | 28 (2%) | 52 (3.7%) | 54 (3.9%) | 680 (48.5%) | 30 (2.1%) | 44 (3.1%) | 136 (9.7%) | 177 (12.6%) | 1402 |
| Ultimately Not Consented | 14 (2%) | 23 (3.3%) | 28 (4%) | 6 (0.8%) | 16 (2.3%) | 23 (3.3%) | 403 (57.1%) | 13 (1.8%) | 24 (3.4%) | 58 (8.2%) | 98 (13.9%) | 706 |
| Ultimately Consented | 25 (3.1%) | 47 (5.9%) | 70 (8.8%) | 23 (2.9%) | 41 (5.2%) | 36 (4.5%) | 332 (41.8%) | 17 (2.1%) | 32 (4%) | 80 (10.1%) | 91 (11.5%) | 794 |
| Referral sources of individuals who recalled or will willing to report how they heard about the IGNITE study. Percentages are specific to each demographic sub-category. For example, 66.2% (141/198) of individuals who identified as African American and reported a referral source heard about the study from direct mailings. All available data used, but referral and/or demographic data are not known for all individuals. Totals may not be equivalent across demographic categories. | ||||||||||||
Reasons for exclusion by demographics.
| Inadequate | Moving Soon | Traveling | Too Active | Impaired | Brain | Cancer | Cardiac | Insulin-Dependent Diabetes | Substance | TICS | MRI | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Men | 0 (0%) | 1 (0.7%) | 23 (15.5%) | 44 (29.7%) | 9 (6.1%) | 25 (16.9%) | 4 (2.7%) | 18 (12.2%) | 5 (3.4%) | 7 (4.7%) | 2 (1.4%) | 10 (6.8%) | 153 (37.9%) |
| Women | 2 (0.8%) | 2 (0.8%) | 34 (13.7%) | 79 (31.9%) | 19 (7.7%) | 52 (21%) | 6 (2.4%) | 8 (3.2%) | 18 (7.3%) | 3 (1.2%) | 7 (2.8%) | 18 (7.3%) | 251 (62.1%) |
| African American | 0 (0%) | 1 (1.6%) | 5 (7.8%) | 15 (23.4%) | 3 (4.7%) | 11 (17.2%) | 4 (6.3%) | 5 (7.8%) | 9 (14.1%) | 4 (6.3%) | 4 (6.3%) | 3 (4.7%) | 67 (17%) |
| Asian | 0 (0%) | 0 (0%) | 4 (44.4%) | 3 (33.3%) | 1 (11.1%) | 1 (11.1%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 9 (2.3%) |
| White | 1 (0.3%) | 1 (0.3%) | 47 (16.2%) | 100 (34.4%) | 18 (6.2%) | 59 (20.3%) | 6 (2.1%) | 18 (6.2%) | 11 (3.8%) | 4 (1.4%) | 1 (0.3%) | 25 (8.6%) | 293 (74.6%) |
| American Indian/Alaska Native | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 2 (100%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 2 (0.5%) |
| Native Hawaiian/Pacific Islander | 0 (0% | 0 (0% | 0 (0% | 0 (0% | 0 (0% | 0 (0% | 0 (0% | 0 (0% | 0 (0% | 0 (0% | 0 (0% | 0 (0% | 0 (0%) |
| Refused | 1 (7.7%) | 0 (0%) | 1 (7.7%) | 0 (0%) | 1 (7.7%) | 4 (30.8%) | 0 (0%) | 1 (7.7%) | 2 (15.4%) | 0 (0%) | 3 (23.1%) | 0 (0%) | 15 (3.8%) |
| Biracial | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (33.3%) | 1 (33.3%) | 0 (0%) | 1 (33.3%) | 0 (0%) | 3 (0.8%) |
| Other | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (25%) | 1 (25%) | 0 (0%) | 0 (0%) | 0 (0%) | 2 (50%) | 0 (0%) | 0 (0%) | 4 (1%) |
| Hispanic/Latino | 0 (0%) | 0 (0%) | 3 (17.6%) | 2 (11.8%) | 1 (5.9%) | 2 (11.8%) | 0 (0%) | 2 (11.8%) | 3 (17.6%) | 0 (0%) | 3 (17.6%) | 1 (5.9%) | 18 (4.6%) |
| Not Hispanic/Latino | 2 (0.5%) | 2 (0.5%) | 54 (14.7%) | 117 (31.8%) | 25 (6.8%) | 74 (20.1%) | 10 (2.7%) | 23 (6.3%) | 19 (5.2%) | 10 (2.7%) | 6 (1.6%) | 26 (7.1%) | 374 (95.4%) |
| Reasons for exclusion of 905 individuals. Age and English fluency are not included as these questions were asked prior to acquiring demographics: 71 individuals were out of age range and 26 were not English fluent (total excluded from the study, n = 1002). Percentages are specific to each demographic sub-category. For example, 7.8% (5/64) of individuals who identified as African Americans reported they would be traveling too frequently during the intervention period. | |||||||||||||
Fig. 2Subgroups of participants identified through classification tree analysis and the proportion of the consented participants by referral source, age (younger than 75 yrs old or not), and gender, the three most influential factors in the likelihood of consent. Race and ethnicity were not sufficiently influential to be included. All modeling done using R package rpart. The minimum number of participants to split the node was set to 100 and complexity parameter to 0.01.
Demographics of randomized participants by site.
| UPitt | KUMC | NEU | Total | Goal | |
|---|---|---|---|---|---|
| Total | 182 | 175 | 130 | 487 | 639 |
| Male | 54 (29.7%) | 49 (28.0%) | 36 (27.7%) | 139 (28.5%) | 195 (40.0%) |
| Female | 128 (70.3%) | 126 (72.0%) | 94 (72.3%) | 348 (71.5%) | 292 (60.0%) |
| African American | 28 (15.4%) | 7 (4.0%) | 26 (20.0%) | 61 (12.5%) | 99 (20.3%) |
| Asian | 1 (0.5%) | 2 (1.1%) | 4 (3.1%) | 7 (1.4%) | 29 (5.9%) |
| White | 151 (83.0%) | 161 (92.0%) | 94 (72.3%) | 406 (83.4%) | 359 (73.8%) |
| American Indian/Alaska Native | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Native Hawaiian/Pacific Islander | 0 (0%) | 1 (0.6%) | 0 (0%) | 1 (0.2%) | 0 (0%) |
| Refused | 2 (1.1%) | 1 (0.6%) | 4 (3.1%) | 7 (1.4%) | 0 (0%) |
| Biracial | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Other | 0 (0%) | 3 (1.7%) | 2 (1.5%) | 5 (1.0%) | 0 (0%) |
| Hispanic/Latino | 2 (1.1%) | 8 (4.6%) | 8 (6.2%) | 18 (3.7%) | 19 (19.0%) |
| Not Hispanic/Latino | 180 (98.9%) | 167 (95.4%) | 122 (93.8%) | 469 (96.3%) | 468 (81.0%) |
| 487 participants have been randomized to date. Percentages are specific to each site or the entire study. | |||||
Fig. 3Cumulative Screenings and Randomizations During the IGNITE Enrollment Period
The figure shows cumulative screenings (solid line), randomizations (dashed line) and the rate of randomizations per 100 screenings (dotted line, right axis) for the enrollment period of Sept. 2017 through Feb. 2020.
Recruitment costs and yield by site.
| Site | Promotional Cost | Staff Cost | Phone Screened | Number | Cost/Randomization | Adjusted Cost/Randomization* | Primary |
|---|---|---|---|---|---|---|---|
| UPitt | $29319 | $33541 | 1214 | 182 | $345.38 | $345.38 | Mailings, advertisement |
| NEU | $35269 | $68167 | 1080 | 130 | $687.92 | $687.92 | Mailings |
| KUMC | $12816 | $97479 | 464 | 175 | $628.32 | $628.32 | Mailings, presentations |
| Total | $77404 | $199,187 | 2758 | 487 | $590.43 | $553.87 | |
| *Per-person randomization costs adjusted by Sept. 2017 Consumer Price Index in each metropolitan area using the 1967 base index for all items, relative to Pittsburgh. | |||||||